Scientific Survey
Cardiovascular diseases (CVDs) continue to impose a significant burden on global healthcare systems, with increasing prevalence and suboptimal control despite preventive efforts. Heart failure (HF) represents a major public health issue, affecting an estimated 45-67 million adults worldwide and leading to higher hospitalization risks, reduced survival rates, and diminished quality of life. The economic implications of HF, including frequent hospitalizations and productivity losses, severely impact countries globally. Pharmacological agents that elevate natriuretic peptides (NPs) have been recommended for managing cardiovascular diseases, and the combination of Sacubitril and Valsartan has shown positive outcomes in hypertension and HF patients. This survey aims to gather valuable insights from esteemed cardiologists regarding their clinical experiences, treatment approaches for heart failure, and expertise in utilizing Sacubitril and Valsartan (ARNIs) for HF management.
Objectives:
1. To share clinical experiences in managing patients with heart failure.
2. To assess the clinical effectiveness, safety, and tolerability of Sacubitril / Valsartan (ARNI) in different patient profiles.
3. To gain insights into other specialists' perspectives on their care delivery strategies aimed at achieving improved outcomes and enhancing patient satisfaction in heart failure management.
Target audience:
Cardiologist